Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Adamas Pharma (NQ: ADMS )

5.240 USD +0.080 (+1.55%)
Streaming Delayed Price Updated: 12:21 PM EDT, Apr 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 105,730
Open 5.160
Bid (Size) 5.210 (1)
Ask (Size) 5.240 (2)
Prev. Close 5.160
Today's Range 5.050 - 5.330
52wk Range 2.430 - 9.150
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026
FinancialNewsMedia.com News Commentary 
From PR Newswire

Performance

YTD
+16.96%
+16.96%
1 Month
-3.68%
-3.68%
3 Month
+15.93%
+15.93%
6 Month
+34.36%
+34.36%
1 Year
+49.29%
+49.29%

More News

Read More
Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinson’s disease presented at American Academy of Neurology (AAN) Annual Meeting
From Business Wire News Releases
Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting
From Business Wire News Releases
Adamas to Present at Upcoming Needham Conference
From Business Wire News Releases
Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskinesia in patients with Parkinson’s disease
From Business Wire News Releases
Adamas Announces New Employment Inducement Grant
From Business Wire News Releases
Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Business Wire News Releases
Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offering
From Business Wire News Releases
Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering
From Business Wire News Releases
Adamas' Gocovri Treatment Doubles ON Time Without Dyskinesia In Parkinson's disease, New Analysis Shows
Tags Parkinson’s Disease Penny Stocks Biotech
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.